Unknown Manufacturer
Levilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis).
Levilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis).
Levilimab is an IL-6 inhibitor originally developed to treat rheumatoid arthiritis. Its actions at IL-6 help augment cytokine storm effects, reducing inflammation.
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
